AbCellera Biologics News

AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation

Seeking AlphaMay 1 11:44 ET

Express News | Abcellera:Under Terms, Abcellera Will Participate as Equity Founding Partner With Potential for Milestones, Royalties on Future Sales of Each Product

ReutersMay 1 09:11 ET

Express News | Abcellera Biologics Inc: Under Terms of Collaboration, Viking and ArrowMark Will Be Majority Shareholders of Newcos

ReutersMay 1 09:10 ET

Express News | Abcellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

ReutersMay 1 09:00 ET

Institutional Owners May Consider Drastic Measures as AbCellera Biologics Inc.'s (NASDAQ:ABCL) Recent US$91m Drop Adds to Long-term Losses

Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders

Simply Wall StApr 22 06:42 ET

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Business WireApr 8 12:05 ET

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Business WireApr 3 16:05 ET

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Yahoo FinanceMar 19 16:05 ET

AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions

AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain fo

BenzingaMar 11 09:03 ET

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera (NASDAQ:ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024,

BusinesswireMar 5 16:30 ET

Insider Stock Buying Reaches US$1.61m On AbCellera Biologics

Over the last year, a good number of insiders have significantly increased their holdings in AbCellera Biologics Inc. (NASDAQ:ABCL). This is encouraging because it indicates that insiders are more opt

Simply Wall StFeb 29 07:50 ET

Peter Thiel Resigns From AbCellera Board for Personal Reasons

Seeking AlphaFeb 23 17:38 ET

AbCellera Announces Resignation of Board Member

AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to

BusinesswireFeb 23 16:30 ET

Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksFeb 23 07:33 ET

AbCellera to Present at Upcoming Investor Conferences in March

AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m.

BusinesswireFeb 22 20:15 ET

Obesity Drugs to Expand U.S. GDP by 1% in the Coming Years: Goldman Sachs

Seeking AlphaFeb 22 14:41 ET

AbCellera Biologics Stock Upgraded to Buy on Q4 Results, R&D Progress

InvestingFeb 22 10:46 ET

AbCellera Biologics Raised to Buy From Hold by Benchmark

AbCellera Biologics Raised to Buy From Hold by Benchmark

Dow JonesFeb 22 07:15 ET

AbCellera Biologics: A Strong Buy on Robust Pipeline and Solid Financial Outlook

TipRanksFeb 22 00:16 ET

Express News | AbCellera Biologics Shares Are Trading Lower After the Company Reported Mixed Q4 Financial Results

Moomoo 24/7Feb 21 10:52 ET